Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study of Ivonescimab Combination Therapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT07245446 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT07245446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07245446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study of Ivonescimab Combination Therapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Lead sponsor
Akeso
Phase
Phase 2
Overall status
Recruiting
Start date
October 29, 2025
Completion date
June 30, 2028
Enrollment
180 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small cell lung cancer (es-sclc)